Immuno-oncology Therapies for the Treatment of Advanced Endometrial Cancer: Which of Your Patients May Benefit from Their Use?

Immuno-oncology Therapies for the Treatment of Advanced Endometrial Cancer: Which of Your Patients May Benefit from Their Use? is organized by Med Learning Group.

Release Date: March 04, 2022
Expiration Date: March 04, 2023

Program Overview:
This enduring TeleECHO program will explore the management of patients with advanced endometrial cancer through interactive case studies. Faculty will review strategies for personalizing the selection of treatment options based on molecular testing and discuss the management of adverse events with immune-oncology/tyrosine kinase inhibitor combination therapies.

Learning Objectives:
Upon the completion of this program, attendees should be able to:
• Critique the rationale supporting the biological features of endometrial cancer (EC) that make it an attractive candidate for the use of immuno-oncology (IO) therapies
• Evaluate evidence from clinical trials assessing available and emerging therapies for the treatment of patients with advanced EC
• Devise strategies to manage the immune-related adverse events (irAEs) and treatment-related adverse events (trAEs) associated IO/tyrosine kinase inhibitor (TKI) combination therapies in development for patients with advanced EC
• Support multidisciplinary care teams for the management of patients with EC